Fennec Announces Results of Annual Meeting

Rhea-AI Summary

Fennec Pharmaceuticals announced the results of its Annual General Meeting of Shareholders held on June 25, 2024, in New York. The nominees listed in the April 29, 2024, management proxy circular were elected as directors, with high approval ratings. Notably, Dr. Khalid Islam received 96.45% of votes in favor, while Mr. Chris A. Rallis received 92.52%. Shareholders also voted 97.96% in favor of appointing Haskell & White LLP as auditors and 93.87% in favor of the executive compensation plan.

Positive

• High approval ratings for board nominees, with Dr. Khalid Islam receiving 96.45% of votes.
• 97.96% shareholder approval for appointing Haskell & White LLP as auditors.
• 93.87% shareholder approval for the executive compensation plan.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024.

Detailed results of the vote for the election of directors are set out below:

Name of Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Dr. Khalid Islam	10,100,238	96.45%	371,270	3.54%
Mr. Chris A. Rallis	9,688,517	92.52%	782,991	7.47%
Mr. Marco Brughera	9,801,305	93.59%	670,203	6.40%
Dr. Jodi Cook	8,991,182	85.86%	1,480,326	14.14%
Mr. Rostislav Raykov	9,859,679	94.15%	611,829	5.84%

Shareholders voted 97.96% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 93.87% in favour of the compensation paid to the Company’s named executive officers.

For further information, please contact:

Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144

FAQ

What were the results of Fennec Pharmaceuticals' Annual General Meeting of Shareholders on June 25, 2024?

The nominees listed in the April 29, 2024, management proxy circular were elected as directors with high approval ratings. Additionally, 97.96% of shareholders voted in favor of appointing Haskell & White LLP as auditors, and 93.87% approved the executive compensation plan.

How did Fennec Pharmaceuticals' shareholders vote on the appointment of auditors?

97.96% of shareholders voted in favor of appointing Haskell & White LLP as auditors.

What percentage of votes did Dr. Khalid Islam receive in the Fennec Pharmaceuticals directors' election?

Dr. Khalid Islam received 96.45% of votes in favor.

What was the shareholder approval rate for Fennec Pharmaceuticals' executive compensation plan?

93.87% of shareholders approved the executive compensation plan.